Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté as Head of Quality
14 December 2021 - 11:30PM
Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a
global leader in the development and delivery of psychedelic
therapies, today announced the launch of its Site Management
Organization Services (“SMO Services”). The SMO Services will
enable companies and researchers developing psychedelic therapies
to use Field Trip’s world class facilities, and expertly trained
medical and therapy teams, to conduct clinical trials. The SMO
Services will be led by Stéphan Côté, who has joined Field Trip as
Head of Quality.
“There are presently over one hundred
psychedelic clinical trials in planning or underway, and many more
likely, as research into psychedelic therapies continues to
accelerate. By adding the SMO Services, we are unlocking additional
revenue drivers from our Field Trip Health centers, and playing
another key part in the future of the psychedelics industry,” said
Joseph del Moral, Field Trip’s Co-Founder and CEO. “Set and setting
play an integral role in the positive outcomes that have been
demonstrated with psychedelic-assisted psychotherapy. By opening up
our locations for clinical research, we are enabling other
researchers and organizations to leverage our world class settings
and highly trained staff.”
Field Trip currently has locations operating in
seven major U.S. cities, making it one of the largest providers of
psychedelic-assisted therapies in North America. Since its
founding, Field Trip’s focus on pairing set and setting with
psychotherapy in connection with its ketamine-assisted therapy
offerings has generated improvements for many of its patients as
measured by depression and anxiety scales, often superior to the
results generated from ketamine IV infusions centers.
Côté, who joins Field Trip as the Head of
Quality, brings more than 25 years of experience in the area of
Quality and Regulatory Compliance. Prior to joining Field Trip,
Côté was Director of Quality Assurance at Impel NeuroPharma where
he led and supported the development and optimization of Impel’s
quality systems and the buildup of the commercial quality and
compliance systems which enabled Impel’s first product launch.
Previously, Côté spent 19 years working in a number of Quality
Assurance roles with Amgen.
In his role with Field Trip, Côté will focus on
development and refinement of the Field Trip’s quality systems to
strategically align with rapid advancement of the Field Trip’s drug
development pipeline and the creation of a clinical research
network and the SMO Services.
“I’m thrilled to join Field Trip at such a
pivotal moment in the company's journey,” said Stéphan Côté, Field
Trip’s Head of Quality. “I look forward to building Field Trip into
a leading network of clinical research sites and the partner of
choice for researchers, CROs and sponsors in the fields of
psychedelic-assisted psychotherapy and other mental health
therapies. We hope to provide the highest quality of services with
a patient-first philosophy. Patient rights, safety, and wellbeing
are, and will always be, our first priority. I believe these
research services will align with Field Trip's mission to help
bring solutions to this seemingly insurmountable global mental
health crisis."
About Field Trip Health
Ltd.
Field Trip is the global leader in the
development and delivery of psychedelic therapies. With our Field
Trip Discovery division leading the development of the next
generation of psychedelic molecules and conducting advanced
research on plant-based psychedelics including psilocybin-producing
fungi and our Field Trip Health division building centers for
psychedelic therapies opening across North America and Europe along
with the digital and technological tools that will enable massive
scale, we help people from those in treatment to those seeking
accelerated personal growth, with a simple, evidence-based way to
heal and heighten engagement with the world.
Learn more at https://www.meetfieldtrip.com,
https://www.fieldtriphealth.com and
https://www.fieldtriphealth.nl.
Follow us on Twitter and Instagram:
@fieldtriphealth
To receive company updates about Field Trip and
to be added to the email distribution list please sign up here.
For further information, contact Ronan Levy,
Executive Chairman and a Director at Field Trip, at 1 (833)
833-1967.
Cautionary Note Regarding
Forward-Looking Information.
This release includes forward-looking
information (within the meaning of Canadian securities laws and
within the meaning of the United States Private Securities
Litigation Reform Act of 1995) regarding Field Trip and its
business. Often but not always, forward-looking information can be
identified by the use of words such as "expect", "intends",
"anticipated", "believes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would" or "will" be
taken, occur or be achieved. Such statements are based on the
current expectations and views of future events of the management
of Field Trip, and are based on assumptions and subject to risks
and uncertainties. Although the management of Field Trip believes
that the assumptions underlying these statements are reasonable,
they may prove to be incorrect. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting the companies, including commencement,
uptake and success of the Site Management Organization (SMO)
Services business , the timing and results of SMO activities, if
any, the opening of additional clinics that can be used as SMO
locations, the COVID-19 epidemic, the medical clinic industry,
market conditions, economic factors, management's ability to manage
and to operate the business and the equity markets generally.
Although Field Trip has attempted to identify important factors
that could cause actual actions, events or results to differ
materially from those described in forward-looking statements,
there may be other factors that cause actions, events or results to
differ from those anticipated, estimated or intended. Accordingly,
readers should not place undue reliance on any forward-looking
statements or information. No forward-looking statement can be
guaranteed. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made and Field Trip does not undertake any obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, or otherwise.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
Media contacts:Autumn
Communications202-276-7881press@fieldtriphealth.com
Investor contacts:Kathleen Heaney / Tim
ReganKCSA Strategic CommunicationsfieldtripIR@kcsa.com
SOURCE Field Trip Health Ltd.
Field Trip Health (NASDAQ:FTRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Field Trip Health (NASDAQ:FTRP)
Historical Stock Chart
From Jul 2023 to Jul 2024